Biosimilar Availability at Hospital Pharmacies in India
Why hospital pharmacies in India struggle with biosimilar availability, covering cold chain, CDSCO approval, interchangeability rules and cost gaps.
This covers why India manufactures so many biosimilars, how CDSCO and DBT approve one, why cold chain is the real bottleneck, what interchangeability rules mean at the pharmacy counter, and what the cost gap against originator biologics means for procurement. Biosimilar availability at a hospital pharmacy, in short, is as much a supply-chain question as a regulatory one.
Why does India manufacture so many of the world's biosimilars?
India had approved over 135 biosimilars by early 2025, one of the largest biosimilar portfolios of any country, built on a mature domestic biotech base India Biosimilars Market report. Biocon Biologics leads the domestic market with over 15% share.
The top five players — Biocon, Intas, Dr. Reddy's, Zydus and Reliance Life Sciences — hold roughly half the market between them. Biocon carries global approvals for trastuzumab, bevacizumab and insulin glargine biosimilars, and holds close to a fifth of the US insulin glargine market on its own. Dr. Reddy's Reditux, launched in 2007, was the world's first rituximab biosimilar Indian regulator approves first trastuzumab similar biologic.
That depth means most major oncology, diabetes and autoimmune biosimilars a hospital wants are made domestically, with fewer import delays than sourcing an originator biologic from abroad. It doesn't mean every approved product reaches every state, or that a hospital's usual distributor stocks the exact brand a doctor prescribed.
How does CDSCO actually approve a biosimilar before it reaches a hospital shelf?
CDSCO and the Department of Biotechnology jointly approve what Indian rules call a "similar biologic" under the 2016 Guidelines on Similar Biologics. Approval needs a tiered dossier: analytical characterisation, preclinical toxicology, then clinical pharmacokinetic and immunogenicity data against a licensed reference product Guidelines on Similar Biologics 2016.
No single regulator signs off alone. A three-member review spanning CDSCO, the Review Committee on Genetic Manipulation and DBT is specific to India, unlike the single-agency model the US FDA or EMA uses.
CDSCO published draft revised guidelines in May 2025 pushing toward newer analytical methods to establish similarity, reducing reliance on animal studies where analytical data alone proves comparability Draft Guidelines on Similar Biologics 2025. Stakeholder comment closed in June 2025; the 2016 framework still governs until that draft is finalised.
A pharmacy should treat CDSCO approval as the regulatory floor, not proof a manufacturer's batch is already in wide circulation. New approvals can take months to reach distributors outside the metros.
Why is cold chain the real stocking bottleneck, not shelf space?
Most biosimilars are injectable proteins — monoclonal antibodies, insulin analogues — that must stay within a labelled 2–8°C range from manufacture to administration. Temperatures outside that range can degrade the protein and cut clinical activity Ridding the Cold Chain for Biologics.
A tablet survives a hot delivery van. A biosimilar vial that spends a few hours above its labelled range may need to be discarded rather than dispensed. That makes this a fundamentally different stocking problem than tablets: validated cold storage at receipt, temperature-logged transport, and a written protocol for a delivery that arrives warm.
Regulators generally expect a defined allowable excursion — for example, a product labelled 2–8°C but validated for a short excursion up to 25°C for 24 hours. Anything beyond that window needs a documented scientific assessment before use. A hospital stocking a biosimilar without a validated cold chain from loading dock to dispensing fridge risks quietly wasting expensive inventory, not a theoretical risk but a routine one.
Does India treat a biosimilar as automatically substitutable for the originator?
No. India has no formal interchangeability designation letting a pharmacist substitute a biosimilar for a prescribed originator, or swap one biosimilar brand for another, without the treating clinician's decision Interchangeability of Biosimilar Monoclonal Antibodies: A Regulatory Perspective. CDSCO approval confirms comparability. It does not authorise pharmacy-level swapping.
A decade of European post-marketing data has not shown increased immunogenicity or reduced efficacy from switching a stable patient between an originator and its biosimilar. But the switch itself stays a prescriber decision, not a default dispensing substitution Interchangeability of biosimilars.
For a hospital pharmacy this is a compliance point, not just a clinical one. Running out of the exact brand a patient was stabilised on does not license handing over a different manufacturer's biosimilar the way a pharmacy might swap paracetamol brands. Doing so without prescriber sign-off sits outside what current Indian rules permit.
What does the biosimilar-versus-originator cost gap look like in practice?
Biosimilars run roughly 60% cheaper than their originator biologic on average globally, and for trastuzumab the gap reaches about 65%, per the World Health Organization's 2025 review of biosimilar access Biosimilars: expanding access to essential biologic therapies. In India, Biocon's trastuzumab biosimilar Canmab cut annual breast cancer treatment cost from roughly ₹15–20 lakh to under ₹5 lakh.
Dr. Reddy's Reditux launched 30–40% below rituximab's originator price Indian regulator approves first trastuzumab similar biologic. The discount is not uniform: it tracks manufacturing complexity and how many competing biosimilars exist per molecule. Insulin glargine biosimilars showed a smaller median 21.6% price decrease across 28 European countries over a decade Insulin glargine prices in 28 European countries.
That gap is exactly what drives hospital procurement toward biosimilars. It only pays off if the product is actually on the shelf. A cost advantage on a price list but not in the fridge sends the patient to an outside chemist anyway, often above the hospital's own negotiated rate.
What happens when a hospital pharmacy can't stock the prescribed brand?
When a hospital pharmacy lacks the specific biosimilar brand a doctor prescribed, the patient pays full originator price outside, or accepts a substitution the prescriber never authorised, given the interchangeability gap above. Either way, revenue and continuity leave the hospital's own pharmacy that day.
This gap shows up most at mid-sized hospitals and nursing homes that lack the volume or cold-chain infrastructure large tertiary centres use to justify multiple biosimilar brands per molecule. A smaller hospital treating occasional oncology cases faces a real trade-off between capital tied up in slow-moving cold-chain stock and a stockout on a drug a patient needs that week.
Batch tracking compounds this. Once a biosimilar leaves the hospital's own dispensing record for an outside pharmacy, the institution loses the ability to trace that patient's treatment back to a specific manufacturer's batch — a real gap if an adverse event surfaces later and needs reporting against the right product Interchangeability of Biosimilar Monoclonal Antibodies: A Regulatory Perspective.
How should a hospital pharmacy decide which biosimilar brands to stock?
A formulary committee should name one default brand per molecule for its most-prescribed biosimilars, reviewed against distributor reliability, cold-chain track record and price. That single rule turns an ad hoc sourcing problem into something the pharmacy can plan and reorder against, rather than chasing whichever distributor has stock that month.
Molecule volume matters. A busy tertiary oncology unit can justify safety stock of a high-turnover biosimilar like trastuzumab or rituximab, given the roughly ₹10 lakh cost gap Canmab represents per patient-year. A smaller facility with occasional prescriptions for the same molecule cannot justify tying up capital in slow-moving cold-chain inventory, and is usually better served pooling that decision with a managed pharmacy partner covering several facilities. Either way, the formulary rule needs a named brand, a named cold-chain protocol and a named reorder threshold, not a general policy of stocking biosimilars "where available." This is, in effect, a biosimilar availability hospital pharmacy planning exercise as much as a clinical formulary one.
Why does reliable in-house biosimilar stocking matter more than it looks?
Reliable in-house stocking of high-cost biosimilars is a hospital-pharmacy operations problem as much as a clinical one, touching cold-chain infrastructure, batch tracking and capital tied up in slow-moving stock at once. Treat it as a one-off purchase rather than a formulary discipline, and a hospital ends up with either wasted cold-chain inventory that expired before it turned over, or repeated stockouts pushing patients and revenue to outside pharmacies.
Managing this well looks like managing any other slow-moving, high-value, expiry-sensitive category, with a temperature-control requirement layered on top. Medyzen's guide on pharmacy inventory management and dead stock covers capital tied up in exactly this kind of slow-turning, high-cost inventory. Our piece on managed hospital pharmacy services covers how pooling procurement and cold-chain infrastructure across a network changes the calculus for a hospital that can't independently justify holding every biosimilar brand it might need.
The same margin logic applies further down the shelf. Our piece on branded versus generic medicine margins covers that trade-off for tablets and capsules, though cold chain and batch tracking make biosimilar stocking considerably more involved than a simple margin comparison.
Sources
- 1Guidelines on Similar Biologics 2016, CDSCO and Department of Biotechnology, Government of India
- 2Draft Guidelines on Similar Biologics 2025, CDSCO, Government of India
- 3Biosimilars: expanding access to essential biologic therapies, World Health Organization
- 4Grand Challenges in Pharmaceutical Research: Ridding the Cold Chain for Biologics, National Institutes of Health, National Library of Medicine
- 5Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective, National Institutes of Health, National Library of Medicine
- 6Are we ready to close the discussion on the interchangeability of biosimilars?, Drug Discovery Today, peer-reviewed
- 7Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries, National Institutes of Health, National Library of Medicine
- 8India Biosimilars Market Size & Share, Forecasts Report, Global Market Insights
- 9Indian regulator approves first trastuzumab 'similar biologic', GaBI Online, Generics and Biosimilars Initiative
- 10Central Drugs Standard Control Organisation, Drugs and Cosmetics Act, 1940 and Rules, 1945
This article is for informational purposes and is not a substitute for professional medical or regulatory advice.
FAQ
Frequently asked questions
CDSCO approval confirms comparability, but says nothing about distributor reach, cold-chain logistics to a specific hospital, or whether that hospital's formulary committee has added the brand to its stocking list. A newly approved biosimilar can take months to reach distributors outside major metros.
Generally no. India has no formal interchangeability designation for biosimilars, so switching a patient between brands, or between an originator and its biosimilar, is a decision for the treating clinician, not a routine pharmacy-level substitution.
Most biosimilars are injectable proteins such as monoclonal antibodies or insulin analogues that must stay within a labelled 2–8°C range. Temperatures outside that range can degrade the protein structure and reduce or eliminate clinical effectiveness, unlike a chemically stable tablet.
It varies by molecule. Biocon's trastuzumab biosimilar Canmab cut annual treatment cost from roughly ₹15–20 lakh to under ₹5 lakh, while Dr. Reddy's Reditux launched 30–40% below rituximab's originator price, reflecting manufacturing complexity and competition per molecule.
Biocon Biologics leads India's biosimilar market with over 15% share, followed by Intas Pharmaceuticals, Dr. Reddy's Laboratories, Zydus Lifesciences and Reliance Life Sciences, which together hold roughly half the domestic market.
Dr. Rajesh IyerMBBS, MD (Pharmacology)
Clinical Pharmacologist
Dr. Rajesh Iyer is a clinical pharmacologist focusing on drug interactions, adverse-effect profiles, biosimilars, and drug-scheduling regulation in India.